Authors
Latest:
COVID-19 and Its Impact on Oncology Clinical TrialsCoronavirus disease 2019 has disrupted oncologic care across the spectrum of cancer screening, diagnosis, and management.
Latest:
Breast Cancer Awareness Month: Recent Developments and Future Directions for Immunotherapy TreatmentMargaret E. Gatti-Mays, MD, MPH, FACP, evaluates the evolution of immunotherapy in cases of breast cancer for Breast Cancer Awareness Month.
Latest:
Choosing BTK Inhibitors Versus Venetoclax as First-Line CLL TherapyNilanjan Ghosh, MD, PhD, discusses when a Bruton’s tyrosine kinase inhibitor would be preferred over a BCL-2 inhibitor as first-line therapy for patients with chronic lymphocytic leukemia.
Latest:
JAVELIN HEAD AND NECK 100 Informs Future Trials in HNSCCThe potential benefit of avelumab in the subgroup of patients with high PD-L1 expression in JAVELIN HEAD AND NECK 100 provides a basis for further investigation and suggests a potential role for immune checkpoint inhibitors for locally advanced HNSCC.
Latest:
Making Treatment and Screening Decisions for Patients With Prostate CancerHagen F. Kennecke, MD, MHA, FRCP, medical oncologist, medical director of the Virginia Mason Cancer Institute and current chair of the NCI Rectal-Anal Cancer Task Force, discusses the treatment and screening decision making process for patients with prostate cancer.
Latest:
Larotrectinib Does Not Increase Risk of Fractures for Thyroid CancerTheodore W. Laetsch, MD, discusses various trials examining larotrectinib in patients with TRK fusion positive thyroid cancer.
Latest:
Rise in Prostate Cancer Cases Contributes to Challenges in CareMurugesan Manoharan, MD, FRACS, offers observations about prostate cancer care at Miami Cancer Institute.
Latest:
Exploring Preliminary Results of Ibrutinib and Fludarabine in CLLChristopher Pleyer, MD, discusses the phase 2 study of ibrutinib and short-course fludarabine in previously untreated patients with chronic lymphocytic leukemia.
Latest:
Advice for Managing Adverse Events of Sacituzumab Govitecan in TNBCRuta D. Rao, MD, discusses her approach to managing adverse events associated with the antibody-drug conjugate sacituzumab govitecan in patients with metastatic triple-negative breast cancer.
Latest:
Neoadjuvant Immunotherapy Expands Its Reach in Metastatic MelanomaA number of novel immunotherapies, such as PD-1 inhibitors and targeted drug therapies with BRAF and MEK inhibitors, have become available for managing advanced melanoma.
Latest:
Treatment Options After Relapse in CLLWojciech Jurczak, MD, PhD, discusses the available treatment options for patients with relapsed/refractory chronic lymphocytic leukemia who relapsed on BCL2 inhibitors.
Latest:
Management of HR+, HER2- Early-Stage Breast Cancer After DiagnosisPhysicians cover the options for a patient with hormone receptor–positive, HER2-negative, early-stage breast cancer, which course of action they would take, and the data supporting that choice.
Latest:
Considerations for Oncologists During Chemotherapy ShortagesRoby Thomas, MD, provides ideas for oncologists to consider while multiple chemotherapy drug are on shortage in the United States.
Latest:
Azacitidine Plus APR-246 Appears Promising as Treatment of TP53-Mutant MDS and AMLThomas Cluzeau, MD, PhD, discusses the rationale for evaluating azacitidine in combination with APR-246 in patients with TP53-mutant myelodysplastic syndrome and acute myeloid leukemia.
Latest:
Future Directions in GVHDPashna Munshi, MD, wraps up by talking about future directions and emerging treatment regimens in the field of GVHD.
Latest:
Background on the Phase 2 Study of Ponatinib/Blinatumomab in Ph+ ALLFadi Haddad, MD, discusses the background of a phase 2 study of blinatumomab in combination with ponatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Latest:
Evaluating Current Challenges in Hepatocellular CarcinomaAnjana Pillai, MD, discusses challenges for treating patients with hepatocellular carcinoma.
Latest:
Ever-Changing Treatment Landscape of Aggressive B-Cell LymphomaJason Westin, MD, MS, FACP, discusses recent developments in novel agents to treat and target aggressive lymphomas.
Latest:
Revised Panobinostat Combination Shows Efficacy in Multiple MyelomaAndrew Spencer, MD, MBBS, discusses the PANORAMA 3 trial data of oral panobinostat plus subcutaneous bortezomib and dexamethasone versus placebo, bortezomib, and dexamethasone.
Latest:
Kidney Cancer Awareness Month: Assessing Best Treatment Options in RCCIn an interview with Targeted Oncology™, Rohan Garje, MD, discussed available therapies, how to assess risks, and manage toxicities for patients with renal cell carcinoma.
Latest:
Cho Provides Background on the Multiple Myeloma Research Foundation’s CureCloud StudyHearn Jay Cho, MD, PhD, discusses the goals of the CureCloud study, an historic initiative of the Multiple Myeloma Research Foundation (MMRF), a leader in the acceleration of efforts to provide precisely the right treatment for each and every patient.
Latest:
Elacestrant Outperforms SOC in Terms of PFS in ER+/HER2– mBCPatients with ER-positive/HER2-negative metastatic breast cancer demonstrated improvement in progression-free survival when administered elacestrant vs standard of endocrine therapy.
Latest:
World Cancer Day: Next Generation Sequencing at the Forefront of Precision MedicineNext generation sequencing is at the forefront of where technology and oncology intersect to help optimize patient outcomes and expand the overall field of cancer care.
Latest:
Research Explores Molecular Subtyping in Prostate Cancer.Adam Weiner, MD, discusses the results of his research on molecular subtyping in prostate cancer.
Latest:
Clinical Benefit Seen With Olaparib/Selumetinib in RAS-Mutated Ovarian and Endometrial CancersThe phase 1b SOLAR trial which evaluated olaparib plus selumetinib in patients with RAS-mutated ovarian or endometrial cancer showed there to be a clinical benefit with the combination.
Latest:
Telehealth Becomes Mainstream in Oncology PracticesDavid W. Dougherty, MD, MBA, discusses telemedicine in oncology after emergence of COVID-19.
Latest:
Investigators Observe Differences in Toxicity for Sarcoma Due to DosingGary K. Schwartz, MD, discusses adverse events seen in patients with metastatic sarcoma participating in the Alliance A091401 trial.
